Douglas R. Lowy, M.D.
Douglas R. Lowy, M.D.
Chief
Senior Investigator
Head, Signaling and Oncogenesis Section
Acting Director, National Cancer Institute

Center for Cancer Research
National Cancer Institute

Building 37, Room 4106C
Bethesda, MD 20892
301-496-9513

Dr. Lowy has two main research areas. One focuses on basic and translational aspects of human papillomavirus infection. His joint research with John Schiller in the Laboratory of Cellular Oncology (LCO) has identified many aspects of the human papillomavirus (HPV) life cycle, developed technology underlying the FDA-approved HPV vaccines, and elucidated mechanisms for the high efficacy of the vaccines. The second area focuses on cancer genes, currently emphasizing the DLC1 tumor suppressor, which encodes a Rho-GAP that is down-regulated in a wide variety of cancers, leading to the high Rho activity seen in many advanced cancers. This research has identified important scaffold functions for DLC1, including protein-protein interactions and phosphorylations, which contribute to the regulation of its activity and its role as a tumor suppressor.

Areas of Expertise
1) cancer biology, 2) papillomaviruses, 3) preventive vaccines, 4) Rho GTPases, 5) signaling, 6) tumor suppressor genes

This laboratory has had a long-term interest in the molecular biology of tumor viruses and growth regulation. Much of the work has focused on fundamental aspects of tumor virology and neoplastic cell growth, but some of the research has direct clinical application. The systems studied include papillomaviruses and signaling through the Rho GTPases.

Papillomaviruses. Papillomaviruses are associated with benign and malignant tumors in humans and animals. A subset of human papillomavirus (HPV) types are responsible for virtually all cases of cervical cancer, which is the third most common cancer among women worldwide, as well as for many cases of anal, vulvar, vaginal, penile, and oropharyngeal cancer. The papillomavirus research is carried out in collaboration with John Schiller's laboratory, which is also in the Laboratory of Cellular Oncology (LCO).

We have developed techniques for large-scale production of virus-like particles (VLPs) composed of papillomavirus structural proteins and high titer pseudoviruses, in which the authentic viral capsid has encapsidated a transducible reporter pseudoviral genome. These reagents have been used to: provide insight into basic aspects of papillomavirus biology; develop preventive VLP-based vaccines, three of which have been approved by the FDA; enable development of the current gold standard in vitro HPV neutralization assay and a second generation in vitro neutralization assay based on the molecular features of in vivo HPV infection; provide evidence that although binding to the target cell is usually the first step in the life cycle of a virus, HPV initiates its life cycle by binding to the acellular basement membrane at sites of disrupted epithelial cell barrier function before the virus transfers to the target epithelial cell; and demonstrate that strong immune responses can be induced by foreign gene expression in the mouse female genital tract, raising the possibility of using pseudoviruses at this site as vectors for vaccination against disease induced by genital infection. The repetitive structure of the VLP is crucial for its high immunogenicity, and the high efficacy of the HPV VLP vaccines is attributable to this strong immunogenicity, to the disrupted tissue barrier at potential sites of infection, which promotes exudation of neutralizing antibodies, and to the exquisite sensitivity of HPV to the neutralizing antibodies induced by the vaccine.

Regulation of Normal and Neoplastic Growth.  Most of our growth regulation research has been concerned with oncogenes and tumor suppressor genes and their signaling pathways as positive and negative regulators of normal and neoplastic growth. In the past, this work was focused on the function of the Ras oncogenes, which are mutated in more than 25% of human cancer. More recently, we have studied molecular aspects of the tumor suppressor gene, DLC1, which encodes a Rho-GAP that is down-regulated in a wide variety of cancers, leading to the high Rho activity seen in many advanced cancers. 

The cell contains several Rho-GAPs that can reduce the activity of Rho GTPases. However, most of them are not frequently down-regulated in cancer, in contrast to DLC1. We have hypothesized that DLC1 possesses important scaffold functions, in addition to its Rho-GAP function, and that this combination of activities leads to its frequent inactivation in cancer. Consistent with this hypothesis, we have found that DLC1 has a variety of scaffold functions that contribute to its tumor suppressor function. The interactions include those between DLC1 and the focal adhesion kinase (FAK), talin, tensin, and caveolin. In addition, CDK5, a predominantly cytoplasmic serine/threonine kinase, phosphorylates several serines in DLC1, which activates the Rho-GAP of DLC1 by converting the protein from being in a closed, inactive conformation to an open, active conformation.

Collaborators on this research include Allan Hildesheim, Mark Schiffman, Aimee Kreimer, Maboobeh Safaeian, and Jeffrey Cohen, NIH; Steven Carr and Philip Mertins, the Broad Institute; Richard Roden, Johns Hopkins; and Rolando Herrero, IARC.

Scientific Focus Areas:
Cancer Biology, Cell Biology, Virology
Selected Recent Publications
  1. Tripathi BK, Qian X, Mertins P, Wang D, Papageorge AG, Carr SA, and Lowy DR.
    J Cell Biol. 207(5): 627-42, 2014. [ Journal Article ]
  2. Schiller JT, Lowy DR
    J Infect Dis. [Epub ahead of print - Nov. 24], 2014. [ Journal Article ]
  3. Cuburu N, Wang K, Goodman KN, Pang YY, Thompson CD, Lowy DR, Cohen JI, and Schiller JT.
    J Virol. 89(1): 83-96, 2015. [ Journal Article ]
  4. Safaeian M, Porras C, Pan Y, Kreimer A, Schiller JT, Gonzalez P, Lowy DR, Wacholder S, Schiffman M, Rodriguez AC, Herrero R, Kemp T, Shelton G, Quint W, van Doorn LJ, Hildesheim A, Pinto LA.
    Cancer Prev Res (Phila). 6: 1242-50, 2013. [ Journal Article ]
  5. Handisurya A, Day PM, Thompson CD, Bonelli M, Lowy DR, and Schiller JT.
    PLoS Pathog. 10(8): e1004314, 2014. [ Journal Article ]

Dr. Lowy received his M.D. from New York University School of Medicine in 1968. Dr. Lowy is the Acting Director of the National Cancer Institute (NCI), National Institutes of Health (NIH), and Chief of the Laboratory of Cellular Oncology. He was Deputy Director of the NCI from 2010 to 2015.  Dr. Lowy received his medical degree from New York University School of Medicine, and trained in internal medicine at Stanford University and dermatology at Yale. He has directed a research laboratory at NCI since 1975, after receiving training as a Research Associate in the National Institute of Allergy and Infectious Diseases. Dr. Lowy is a member of the National Academy of Sciences (NAS) and of the Institute of Medicine of the NAS. For his joint research with John Schiller on technology that enabled the preventive HPV vaccines, he and Dr. Schiller have jointly received numerous honors, including the 2007 Federal Employee of the Year Service to America Medal from the Partnership for Public Service, the 2011 Albert B. Sabin Gold Medal Award, and the 2012 National Medal of Technology & Innovation (awarded in 2014).  Dr. Lowy has also received the National Medal of Honor for Basic Research from the American Cancer Society.

Name Position
Richard Braverman M.S. Research Chemist
Xiaoli Du Postdoctoral Fellow (Visiting)
Tiera Grant Student (IRTA)
Rhonda Kines Ph.D. Special Volunteer
Xi Liu Ph.D. Postdoctoral Fellow (Visiting)
Lloyd G. Mitchell M.D. Guest Researcher
Alex G. Papageorge M.S. Research Biologist
Xiaolan Qian Ph.D. Staff Scientist
Jeffrey Roberts Ph.D. Special Volunteer
Beatriz Sanchez-Solana Ph.D. Postdoctoral Fellow (CRTA)
Brajendra Tripathi Research Fellow
William C. Vass M.S. Research Biologist

Summary

Dr. Lowy has two main research areas. One focuses on basic and translational aspects of human papillomavirus infection. His joint research with John Schiller in the Laboratory of Cellular Oncology (LCO) has identified many aspects of the human papillomavirus (HPV) life cycle, developed technology underlying the FDA-approved HPV vaccines, and elucidated mechanisms for the high efficacy of the vaccines. The second area focuses on cancer genes, currently emphasizing the DLC1 tumor suppressor, which encodes a Rho-GAP that is down-regulated in a wide variety of cancers, leading to the high Rho activity seen in many advanced cancers. This research has identified important scaffold functions for DLC1, including protein-protein interactions and phosphorylations, which contribute to the regulation of its activity and its role as a tumor suppressor.

Areas of Expertise
1) cancer biology, 2) papillomaviruses, 3) preventive vaccines, 4) Rho GTPases, 5) signaling, 6) tumor suppressor genes

Research

This laboratory has had a long-term interest in the molecular biology of tumor viruses and growth regulation. Much of the work has focused on fundamental aspects of tumor virology and neoplastic cell growth, but some of the research has direct clinical application. The systems studied include papillomaviruses and signaling through the Rho GTPases.

Papillomaviruses. Papillomaviruses are associated with benign and malignant tumors in humans and animals. A subset of human papillomavirus (HPV) types are responsible for virtually all cases of cervical cancer, which is the third most common cancer among women worldwide, as well as for many cases of anal, vulvar, vaginal, penile, and oropharyngeal cancer. The papillomavirus research is carried out in collaboration with John Schiller's laboratory, which is also in the Laboratory of Cellular Oncology (LCO).

We have developed techniques for large-scale production of virus-like particles (VLPs) composed of papillomavirus structural proteins and high titer pseudoviruses, in which the authentic viral capsid has encapsidated a transducible reporter pseudoviral genome. These reagents have been used to: provide insight into basic aspects of papillomavirus biology; develop preventive VLP-based vaccines, three of which have been approved by the FDA; enable development of the current gold standard in vitro HPV neutralization assay and a second generation in vitro neutralization assay based on the molecular features of in vivo HPV infection; provide evidence that although binding to the target cell is usually the first step in the life cycle of a virus, HPV initiates its life cycle by binding to the acellular basement membrane at sites of disrupted epithelial cell barrier function before the virus transfers to the target epithelial cell; and demonstrate that strong immune responses can be induced by foreign gene expression in the mouse female genital tract, raising the possibility of using pseudoviruses at this site as vectors for vaccination against disease induced by genital infection. The repetitive structure of the VLP is crucial for its high immunogenicity, and the high efficacy of the HPV VLP vaccines is attributable to this strong immunogenicity, to the disrupted tissue barrier at potential sites of infection, which promotes exudation of neutralizing antibodies, and to the exquisite sensitivity of HPV to the neutralizing antibodies induced by the vaccine.

Regulation of Normal and Neoplastic Growth.  Most of our growth regulation research has been concerned with oncogenes and tumor suppressor genes and their signaling pathways as positive and negative regulators of normal and neoplastic growth. In the past, this work was focused on the function of the Ras oncogenes, which are mutated in more than 25% of human cancer. More recently, we have studied molecular aspects of the tumor suppressor gene, DLC1, which encodes a Rho-GAP that is down-regulated in a wide variety of cancers, leading to the high Rho activity seen in many advanced cancers. 

The cell contains several Rho-GAPs that can reduce the activity of Rho GTPases. However, most of them are not frequently down-regulated in cancer, in contrast to DLC1. We have hypothesized that DLC1 possesses important scaffold functions, in addition to its Rho-GAP function, and that this combination of activities leads to its frequent inactivation in cancer. Consistent with this hypothesis, we have found that DLC1 has a variety of scaffold functions that contribute to its tumor suppressor function. The interactions include those between DLC1 and the focal adhesion kinase (FAK), talin, tensin, and caveolin. In addition, CDK5, a predominantly cytoplasmic serine/threonine kinase, phosphorylates several serines in DLC1, which activates the Rho-GAP of DLC1 by converting the protein from being in a closed, inactive conformation to an open, active conformation.

Collaborators on this research include Allan Hildesheim, Mark Schiffman, Aimee Kreimer, Maboobeh Safaeian, and Jeffrey Cohen, NIH; Steven Carr and Philip Mertins, the Broad Institute; Richard Roden, Johns Hopkins; and Rolando Herrero, IARC.

Scientific Focus Areas:
Cancer Biology, Cell Biology, Virology

Publications

Selected Recent Publications
  1. Tripathi BK, Qian X, Mertins P, Wang D, Papageorge AG, Carr SA, and Lowy DR.
    J Cell Biol. 207(5): 627-42, 2014. [ Journal Article ]
  2. Schiller JT, Lowy DR
    J Infect Dis. [Epub ahead of print - Nov. 24], 2014. [ Journal Article ]
  3. Cuburu N, Wang K, Goodman KN, Pang YY, Thompson CD, Lowy DR, Cohen JI, and Schiller JT.
    J Virol. 89(1): 83-96, 2015. [ Journal Article ]
  4. Safaeian M, Porras C, Pan Y, Kreimer A, Schiller JT, Gonzalez P, Lowy DR, Wacholder S, Schiffman M, Rodriguez AC, Herrero R, Kemp T, Shelton G, Quint W, van Doorn LJ, Hildesheim A, Pinto LA.
    Cancer Prev Res (Phila). 6: 1242-50, 2013. [ Journal Article ]
  5. Handisurya A, Day PM, Thompson CD, Bonelli M, Lowy DR, and Schiller JT.
    PLoS Pathog. 10(8): e1004314, 2014. [ Journal Article ]

Biography

Dr. Lowy received his M.D. from New York University School of Medicine in 1968. Dr. Lowy is the Acting Director of the National Cancer Institute (NCI), National Institutes of Health (NIH), and Chief of the Laboratory of Cellular Oncology. He was Deputy Director of the NCI from 2010 to 2015.  Dr. Lowy received his medical degree from New York University School of Medicine, and trained in internal medicine at Stanford University and dermatology at Yale. He has directed a research laboratory at NCI since 1975, after receiving training as a Research Associate in the National Institute of Allergy and Infectious Diseases. Dr. Lowy is a member of the National Academy of Sciences (NAS) and of the Institute of Medicine of the NAS. For his joint research with John Schiller on technology that enabled the preventive HPV vaccines, he and Dr. Schiller have jointly received numerous honors, including the 2007 Federal Employee of the Year Service to America Medal from the Partnership for Public Service, the 2011 Albert B. Sabin Gold Medal Award, and the 2012 National Medal of Technology & Innovation (awarded in 2014).  Dr. Lowy has also received the National Medal of Honor for Basic Research from the American Cancer Society.

Team

Name Position
Richard Braverman M.S. Research Chemist
Xiaoli Du Postdoctoral Fellow (Visiting)
Tiera Grant Student (IRTA)
Rhonda Kines Ph.D. Special Volunteer
Xi Liu Ph.D. Postdoctoral Fellow (Visiting)
Lloyd G. Mitchell M.D. Guest Researcher
Alex G. Papageorge M.S. Research Biologist
Xiaolan Qian Ph.D. Staff Scientist
Jeffrey Roberts Ph.D. Special Volunteer
Beatriz Sanchez-Solana Ph.D. Postdoctoral Fellow (CRTA)
Brajendra Tripathi Research Fellow
William C. Vass M.S. Research Biologist